Patents by Inventor Yoshinori Murata

Yoshinori Murata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7306682
    Abstract: An object of this invention is to provide a single-crystal nickel-based superalloy having high creep rupture strength at high temperatures and excel at corrosion resistance and oxidation resistance at high temperatures. Single-crystal nickel-based superalloys with high temperature strength, hot corrosion resistance and oxidation resistance comprising by weight, 3.0 to 7.0% Cr, 9.5 to 15.0% Co, 4.5 to 8.0% W, 3.3 to 6.0% Re, 4.0 to 8.0% Ta, 0.8 to 2.0% Ti, 4.5 to 6.5% Al, 0.01 to 0.2% Hf, less than 0.5% Mo, 0.01% or less C, 0.005% or less B, 0.01% or less Zr, 0.005% or less O, 0.005% or less N, and balance substantially Ni.
    Type: Grant
    Filed: August 10, 2004
    Date of Patent: December 11, 2007
    Assignees: Hitachi, Ltd., The Kansai Electric Power Co., Inc., Masahiko Morinaga, Yoshinori Murata
    Inventors: Akira Yoshinari, Ryokichi Hashizume, Masahiko Morinaga, Yoshinori Murata
  • Publication number: 20070235110
    Abstract: Nickel based superalloys with excellent mechanical strength, corrosion resistance and oxidation resistance, which consist essentially of chromium in an amount of 3 to 7% by weight, cobalt in an amount of 3 to 15% by weight, tungsten in an amount of 4.5 to 8% by weight, rhenium in an amount of 3.3 to 6% by weight, tantalum in an amount of 4 to 8% by weight, titanium in an amount of 0.8 to 2% by weight, aluminum in an amount of 4.5 to 6.5% by weight, ruthenium in an amount of 0.1 to 6%, hafnium in an amount of 0.01 to 0.2% by weight, molybdenum in an amount of less than 0.5% by weight, carbon in an amount 0.06% by weight or less, boron in an amount of 0.01% by weight or less, zirconium in an amount of 0.01% by weight or less, oxygen in an amount of 0.005% by weight or less, nitrogen in an amount of 0.005% by weight or less and inevitable impurities and the balance being nickel.
    Type: Application
    Filed: August 29, 2005
    Publication date: October 11, 2007
    Inventors: Akira Yoshinari, Ryokichi Hashizume, Masahiko Morinaga, Yoshinori Murata
  • Publication number: 20070195376
    Abstract: A facsimile machine receives image data from a facsimile machine of another end. A Random Access Memory (RAM) stores a measured average value and fluctuation of an Eye Quality Monitor (EQM) value of the image data, and a number of error lines of the image data as an EQM data table. In past facsimile communication, a main control unit receives a training signal from the facsimile machine of the other end, and executes a training process. The main control unit measures an average value and fluctuation of an EQM value of the training signal, and compares the measured average value and the fluctuation of the EQM value with the average value and the fluctuation of the EQM value stored in the EQM data table. When there is no match, the main control unit executes the training process again.
    Type: Application
    Filed: February 1, 2007
    Publication date: August 23, 2007
    Applicant: MURATA KIKAI KABUSHIKI KAISHA
    Inventors: Yasuki Imai, Yoshinori Murata
  • Patent number: 7009721
    Abstract: A user uses a control panel (13) to specify quick memory transmission and instruct the machine to begin the procedure. The first page of the document is scanned in by a scanning unit (14) and stored in a image memory (19). Upon storing of the image of the first page of the document in the image memory (19), NCU (17) automatically dials a transmission recipient. Additionally, a monitoring unit (16) allows the user to hear the sounds of the communication signals at the start of transmission. If, during the scanning of a second, third, or later page of a multi-page document, free space in the image memory (19) falls below a given value, then the page at which the memory became full is indicated to the user, thereby indicating the page at which retransmission should begin.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: March 7, 2006
    Assignee: Murata Kikai Kabushiki Kaisha
    Inventor: Yoshinori Murata
  • Publication number: 20050277673
    Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
    Type: Application
    Filed: June 14, 2005
    Publication date: December 15, 2005
    Inventors: Koji Ando, Satoru Iguchi, Noriaki Murase, Yoshinori Murata, Toyoharu Numata, Hiroki Sone, Chikara Uchida, Tatsuo Ueki
  • Publication number: 20050277671
    Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
    Type: Application
    Filed: June 14, 2005
    Publication date: December 15, 2005
    Inventors: Koji Ando, Satoru Iguchi, Noriaki Murase, Yoshinori Murata, Toyoharu Numata, Hiroki Sone, Chikara Uchida, Tatsuo Ueki
  • Publication number: 20050277672
    Abstract: This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
    Type: Application
    Filed: June 14, 2005
    Publication date: December 15, 2005
    Inventors: Koji Ando, Satoru Iguchi, Noriaki Murase, Yoshinori Murata, Toyoharu Numata, Hiroki Sone, Chikara Uchida, Tatsuo Ueki
  • Patent number: 6877124
    Abstract: A communication terminal device (F) having an error correction function defined in ITU-T Recommendations T.30. The communication terminal device includes a modem (3) that can transmit data to a remote device in accordance with a plurality of modulation methods and communication speeds. A controller (1) associated with the terminal device (F) changes a current modulation method of the modem (3) to a different modulation method when an all-frame-error is detected predetermined times during data transmission. The controller (1), however, maintains the current modulation method and reduces a communication speed when a frame error other than the all-frame-error is detected prescribed times.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: April 5, 2005
    Assignee: Murata Kikai Kabushiki Kaisha
    Inventor: Yoshinori Murata
  • Publication number: 20050067062
    Abstract: An object of this invention is to provide a single-crystal nickel-based superalloy having high creep rupture strength at high temperatures and excel at corrosion resistance and oxidation resistance at high temperatures. Single-crystal nickel-based superalloys with high temperature strength, hot corrosion resistance and oxidation resistance comprising by weight, 3.0 to 7.0% Cr, 9.5 to 15.0% Co, 4.5 to 8.0% W, 3.3 to 6.0% Re, 4.0 to 8.0% Ta, 0.8 to 2.0% Ti, 4.5 to 6.5% Al, 0.01 to 0.2% Hf, less than 0.5% Mo, 0.01% or less C, 0.005% or less B, 0.01% or less Zr, 0.005% or less O, 0.005% or less N, and balance substantially Ni.
    Type: Application
    Filed: August 10, 2004
    Publication date: March 31, 2005
    Applicants: HITACHI, LTD., The Kansai Electric Power Co., Inc., Masahiko Morinaga, Yoshinori Murata
    Inventors: Akira Yoshinari, Ryokichi Hashizume, Masahiko Morinaga, Yoshinori Murata
  • Publication number: 20040181062
    Abstract: This invention provides a compound of the following formula: 1
    Type: Application
    Filed: February 5, 2004
    Publication date: September 16, 2004
    Applicant: Pfizer Inc
    Inventors: Yoshiyuki Okumura, Yoshinori Murata, Takashi Mano
  • Patent number: 6713482
    Abstract: This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X1 and X2 are independently selected from halo, C1-C4 alkyl, hydroxy, C1-C4 alkoxy, amino, C1-C4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C1-C4 alkyl)thio, (C1-C4 alkyl)sulfinyl, (C1-C4 alkyl)sulfonyl, aminosulfonyl, or the like; R1 is selected from hydrogen, straight or branched C1-C4 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkenyl, phenyl, heteroaryl and the like; R2 and R3 are independently selected from hydrogen, halo, C1-C4 alkyl, phenyl and the like; or R1 and R2 can form, together with the carbon atom to which they are attached, a C5-C7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: March 30, 2004
    Assignee: Pfizer Inc.
    Inventors: Yoshiyuki Okumura, Yoshinori Murata, Takashi Mano
  • Patent number: 6713430
    Abstract: A leaf of printed matter has a metachromatic image 2 printed with an ink thermally changing its color and a non-metachromatic image 3 of a colorant not changing its color. A principal figure 5 is formed of the colorant, and a background 6 is formed with the metachromatic ink. The printed matter 1 may be used to transfer its images to a cup 10. The ink of the background scene 6 in the outer layer will turn to colorless within a prescribed range of temperatures, rendering visible only the central principal figure 5. At lower temperatures, the metachromatic ink will restore its color to cause the background for instance a snowy scene to appear, thus affording a novel and fantastic visual effect.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: March 30, 2004
    Assignee: Sakura Color Products Corporation
    Inventors: Nakao Tominaga, Yoshinori Murata
  • Publication number: 20030024609
    Abstract: In the thermal power system, the electricity production efficiency may be improved by providing turbine members having the improved high temperature characteristic over the corresponding prior art turbine members. Turbine members may be provided by using high resistant steels composed of any one or ones selected from the group consisting of the components, including 0.08 to 0.13% of carbon (C), 8.5 to 9.8% of chromium (Cr), 0 to 1.5% of molybdenum (Mo), 0.10 to 0.25% of vanadium (V), 0.03 to 0.08% of niobium (Nb), 0.2 to 5.0% of tungsten (W), 1.5 to 6.0% of cobalt (Co), 0.002 to 0.015% of boron (B), 0.015 to 0.025% of nitrogen (N), and optionally, 0.01 to 3.0% of rhenium (Re), 0.1 to 0.50% of silicon (Si), 0.1 to 1.0% of manganese (Mo), 0.05 to 0.8% of nickel (Ni) and 0.1 to 1.3% of cupper.
    Type: Application
    Filed: July 16, 2002
    Publication date: February 6, 2003
    Inventors: Masahiko Morinaga, Yoshinori Murata, Tsukasa Azuma, Kazuhiro Miki, Tohru Ishiguro, Ryokichi Hashizume
  • Patent number: 6509980
    Abstract: A facsimile apparatus (device) having a plurality of lines connected thereto and which is capable of make facsimile communication in the parallel use of these lines. More specifically, when a plurality set of data is being received through two or more lines in parallel, the facsimile device of the present invention allows the set of data that has completed storage of its first one page content most quickly to preferentially use a printer. Then that set of data is allowed to continue delivering the hard copy of whole pages and releases the printer after completing the delivery. The image data of the other set of data that was not able to occupy the printer is stored in the memory and printed out after the release of the printer. As each entire page of a set of data is successively output, image data of other sets of data is never mixed with the currently output one.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: January 21, 2003
    Assignee: Murata Kikai Kabushiki Kaisha
    Inventor: Yoshinori Murata
  • Publication number: 20030013886
    Abstract: This invention provides a compound of the following formula: 1
    Type: Application
    Filed: August 8, 2001
    Publication date: January 16, 2003
    Inventors: Yoshiyuki Okumura, Yoshinori Murata, Takashi Mano
  • Publication number: 20020097442
    Abstract: A communication terminal device transmits an ANSam signal (step S2). When the device does not detect a CM signal within a prescribed period (NO in step S3 and YES in step S4), the device transmits a DIS signal with a bit indicating that the communication procedure of the V.8 mode can be carried out (step S5). Then, when receiving a CI signal (YES in step S6), the device transmits an ANSam signal (step S21 in FIG. 3), and afterwards if a CM signal cannot be detected (NO in step 22), and the number of detected CI signals is a prescribed number or more (YES in step S25), the device transmits a DIS signal without a bit indicating that the communication procedure in accordance with V.8 mode can be carried out (step S26).
    Type: Application
    Filed: January 3, 2002
    Publication date: July 25, 2002
    Applicant: MURATA KIKAI KABUSHIKI KAISHA
    Inventor: Yoshinori Murata
  • Patent number: 6417202
    Abstract: The present invention provides a compound of the formula: and its pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5 and m are as defined in claim 1. The present invention also provides processes for the preparation thereof, the use thereof in treating cytokines mediated diseases and/or cell adhesion molecules (CAMs) mediated diseases and pharmaceutical compositions for use in such therapy.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: July 9, 2002
    Assignee: Pfizer Inc.
    Inventors: Akiyoshi Kawai, Makoto Kawai, Yoshinori Murata, Junji Takada, Minoru Sakakibara
  • Publication number: 20020049235
    Abstract: The present invention provides a compound of the formula: 1
    Type: Application
    Filed: December 10, 1999
    Publication date: April 25, 2002
    Inventors: AKIYOSHI KAWAI, MAKOTO KAWAI, YOSHINORI MURATA, JUNJI TAKADA, MINORU SAKAKIBARA
  • Patent number: 6310079
    Abstract: This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof, wherein Ar is heteroaryl; X1 and X2 are independently selected from halo, C1-C4 alkyl, hydroxy, C1-C4 alkoxy, amino, C1-C4 alkanoyl, carboxy, carbamoyl, cyano, nitro, mercapto, (C1-C4 alkyl)thio, (C1-C4 alkyl)sulfinyl, (C1-C4 alkyl)sulfonyl, aminosulfonyl, or the like; R1 is selected from hydrogen, straight or branched C1-C4 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkenyl, phenyl , heteroaryl and the like; R2 and R3 are independently selected from hydrogen, halo, C1-C4 alkyl, phenyl and the like; or R1 and R2 can form, together with the carbon atom to which they are attached, a C5-C7 cycloalkyl ring; and m and n are independently 0, 1, 2 or 3. These compounds and pharmaceutical compositions containing such compounds are useful as analgesics and anti-inflammatory agents.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: October 30, 2001
    Assignee: Pfizer Inc.
    Inventors: Yoshiyuki Okumura, Yoshinori Murata, Takashi Mano
  • Publication number: 20010031702
    Abstract: A leaf of printed matter has a metachromatic image 2 printed with an ink thermally changing its color and a non-metachromatic image 3 of a colorant not changing its color. A principal FIG. 5 is formed of the colorant, and a background 6 is formed with the metachromatic ink. The printed matter 1 may be used to transfer its images to a cup 10. The ink of the background scene 6 in the outer layer will turn to colorless within a prescribed range of temperatures, rendering visible only the central principal FIG. 5. At lower temperatures, the metachromatic ink will restore its color to cause the background for instance a snowy scene to appear, thus affording a novel and fantastic visual effect.
    Type: Application
    Filed: April 9, 2001
    Publication date: October 18, 2001
    Inventors: Nakao Tominaga, Yoshinori Murata